Functional and morphological characterization of neuropathy induced with 5-lipoxygenase inhibitor CGS 21595.
Peripheral toxic neuropathy induced in rats with a 5-lipoxygenase inhibitor CGS 21,595 was characterized using special functional tests and pathological procedures. Functional tests included measurement of grip strength, landing foot splay, assessment of sensorimotor and autonomic functions and monitoring of motor activity. Pathological procedures consisted of perfusion fixation, embedding in plastic, teasing of isolated nerve fibers, and light and electron microscopy. Male and female albino rats received the test article orally by gavage on 5 days per week. To characterize the development of the lesion animals treated with 1000 mg/kg were examined and sacrificed at 2-week intervals until termination at 10 weeks. In a separate study, the dose-effect relationship was examined in groups of animals treated with 50,200 or 1000 mg/kg for 10 weeks. Neurotoxicity occurred only in animals treated with 1000 mg/kg and was first detected following 4 weeks of treatment. Although there were no overt clinical signs of neurotoxicity, functional examination detected a reduction of grip strength, increased landing foot splay and reduced motor activity. Neuropathological examination revealed peripheral segmental demyelination affecting predominantly the Schwann cells in the ventral spinal nerve roots. Owing to its unusual localization in the nervous system and to subtlety of functional signs, peripheral segmental demyelination represents a special diagnostic challenge in toxicological safety studies.
Classen
W
W
CIBA-GEIGY Ltd., Toxicology Services, Basle, Switzerland.
Gunson
D E
DE
Iverson
W O
WO
Traina
V M
VM
Vonau
M H
MH
Krinke
G J
GJ
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000633:toxicity; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D016859:Lipoxygenase Inhibitors; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley
D016859:Lipoxygenase Inhibitors; C075704:CGS 21595; D015057:1-Naphthylamine